USDA has given Boehringer Ingelheim the green light to import TUR-3, a killed vaccine currently licensed for use throughout Europe for Newcastle disease, avian paramyxovirosis type 3 and turkey rhinotracheitis.
TUR-3 will be available for primary vaccination of US turkey and chicken flocks against avian metapneumovirus (aMPV) subtype B, which results in severe respiratory symptoms and increased mortality in poultry as well as a decrease in egg production.
“US poultry producers have been challenged by aMPV, and it’s positive news that our TUR-3 vaccine will be available as a tool to support USDA and industry efforts to protect flocks against this highly contagious respiratory disease,” said Steve Boren, head of the Boehringer Ingelheim US Livestock and Equine business.
Boehringer responded to a request by the USDA Center for Veterinary Biologics (CVB) for vaccines to protect against the virus. There is no vaccine currently licensed in the US to address this disease challenge.
“By leveraging the Boehringer global supply network, we were able to respond to USDA’s call for vaccines and support poultry producers who have been impacted by the virus,” Boren added.
TUR-3 is expected to be available in the US in November. It is permitted for use domestically in turkeys and chickens. Customers should contact their local Boehringer representative for additional product information.
Editor’s note: Content on Modern Poultry’s Industry Insights pages is provided and/or commissioned by our sponsors, who assume full responsibility for its accuracy and compliance.
